Abstract PO-224: Disproportional representation of racial and ethnic minorities in colorectal cancer clinical trials

152 Background: Extensive attention has been paid in recent years to the possibility that bias among health care professionals contributes to health disparities. In its 2003 report, Unequal Treatment, the Institute of Medicine concluded that bias against racial minorities may affect communication or care offered. However, the role of bias in the context of recruitment of racial minorities in cancer clinical trials has not been explored. Therefore, we assessed clinical and research personnel’s experiences related to factors influencing recruitment of racial and ethnic minorities for cancer clinical trials. Methods: Ninety-one qualitative interviews were conducted at 5 U.S. cancer centers among 4 stakeholder groups: cancer center leaders, principal investigators, referring clinicians and research staff. Data analysis was conducted using a content analysis approach to generate themes from the transcribed interviews. Results: Five prominent themes emerged. 1) Recruitment interactions with potential minority participants were perceived to be challenging. 2) Potential minority participants were not perceived to be ideal study candidates. 3) A combination of clinic level barriers and negative perceptions of minority study participants led to providers withholding clinical trial opportunities from potential minority participants. 4) When clinical trial recruitment practices were tailored to minority patients, addressing research misconceptions to build trust was a common strategy. 5) For some respondents, race was perceived as irrelevant when screening and recruiting potential minority participants for clinical trials. Conclusions: Not only did some respondents view racial and ethnic minorities as less promising participants, some respondents reported withholding trial opportunities to minorities based on these perceptions. Some providers endorsed using tailored recruitment strategies while others eschewed race as a factor in trial recruitment. The presence of bias and stereotyping among clinical and research professionals recruiting for cancer clinical trials, should be considered when designing interventions to increase minority enrollment.

Download Full-text

Signaling inhibition with radiation in colorectal cancer: Clinical trials

Seminars in Oncology ◽

10.1016/s0093-7754(03)00126-x ◽

2003 ◽

Vol 30 (3 Suppl 6) ◽

pp. 56-67 ◽

Cited By ~ 3

Author(s):

W. Gillies McKenna ◽

Ruth J. Muschel ◽

Anjali Gupta ◽

Stephen Hahn ◽

Eric J. Bernhard

Keyword(s):

Colorectal Cancer ◽

Clinical Trials ◽

Cancer Clinical Trials

Download Full-text

Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2018.07.262 ◽

2018 ◽

Vol 24 (8) ◽

pp. S58-S59

Author(s):

Ayman Samman Tahhan ◽

Muthiah Vaduganathan ◽

Stephen Greene ◽

Gregg Fonarow ◽

Mona Fiuzat ◽

...

Keyword(s):

Heart Failure ◽

Clinical Trials ◽

Ethnic Minorities ◽

Older Patients ◽

Racial And Ethnic Minorities

Download Full-text

The Coalition of cancer cooperative groups GI scientific leadership council

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.13522 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 13522-13522

Author(s):

R. B. Catalano ◽

R. L. Comis ◽

M. J. O’Connell

Keyword(s):

Colorectal Cancer ◽

Clinical Trials ◽

Pharmaceutical Industry ◽

Research Priorities ◽

Science Research ◽

The United States ◽

Advisory Group ◽

Cancer Clinical Trials ◽

Cooperative Groups ◽

Patient Advocate

13522 Background: The Coalition of Cancer Cooperative Groups convened the GI Scientific Leadership Council (GI SLC) to provide leadership in establishing and advancing national research priorities for colorectal cancer clinical trials. A key objective was to complement and enhance the scientific programs of the NCI-sponsored GI Intergroup. Methods: A multidisciplinary group of investigators representing the spectrum of diagnostic, therapeutic, and laboratory disciplines engaged in colorectal cancer clinical research was convened in December 2004 to address the most important research opportunities in colorectal cancer, and clinical trials to address those opportunities. In April 2005, the concepts evolved were discussed with representatives of the patient advocate community and the pharmaceutical industry. In December 2005 the GI SLC presented its core research recommendations to more than 100 members of the cancer community. Results: Seven principal cross-cutting themes emerged, as well as ten strategic recommendations to be addressed over the next three years. A portfolio of high priority clinical trials was identified. The GI SLC has prioritized support for three colon cancer surgical adjuvant trials; two rectal cancer surgical adjuvant trials; two colorectal cancer metastatic to the liver trials; two metastatic colorectal trials; and one colon polyp and cancer detection study trial. These will be detailed in our presentation. Conclusions:The GI Scientific Leadership Council represents a novel approach to strengthen colorectal cancer clinical trials and correlative science research in the United States by providing a platform to bring together clinical investigators and translational researchers, the patient advocate community, and the pharmaceutical industry. The GI SLC plans to convene a Cancer Prevention Advisory Group in the first quarter of 2006 and plans to initiate one or more innovative clinical trials in collaboration with industry in 2006. The GI SLC will meet throughout 2006 to develop action plans, review progress towards those plans, and facilitate adoption of the research priorities across the cancer community. No significant financial relationships to disclose.

Download Full-text

Recruitment of racial and ethnic minorities to clinical trials conducted within specialty clinics: an intervention mapping approach

Trials ◽

10.1186/s13063-018-2507-9 ◽

2018 ◽

Vol 19 (1) ◽

Cited By ~ 8

Author(s):

Rossybelle P. Amorrortu ◽

Mariana Arevalo ◽

Sally W. Vernon ◽

Arch G. Mainous ◽

Vanessa Diaz ◽

...

Keyword(s):

Clinical Trials ◽

Ethnic Minorities ◽

Intervention Mapping ◽

Racial And Ethnic Minorities ◽

Mapping Approach

Download Full-text

Turning Point for Colorectal Cancer Clinical Trials

Journal of Clinical Oncology ◽

10.1200/jco.2006.06.6118 ◽

2006 ◽

Vol 24 (21) ◽

pp. 3322-3324 ◽

Cited By ~ 3

Author(s):

Neal J. Meropol

Keyword(s):

Colorectal Cancer ◽

Clinical Trials ◽

Turning Point ◽

Cancer Clinical Trials

Download Full-text

Personal and contextual factors in substance abuse treatment among racial and ethnic minorities: Studies from the NIDA clinical trials network

Journal of Ethnicity in Substance Abuse ◽

10.1080/15332640.2017.1409951 ◽

2017 ◽

Vol 16 (4) ◽

pp. 401-403 ◽

Cited By ~ 2

Author(s):

A. Kathleen Burlew ◽

Katherine Sanchez

Keyword(s):

Substance Abuse ◽

Clinical Trials ◽

Substance Abuse Treatment ◽

Ethnic Minorities ◽

Contextual Factors ◽

Racial And Ethnic Minorities ◽

Abuse Treatment

Download Full-text

The Systemic Exclusion of Native Americans from Cancer Clinical Trials.

10.31219/osf.io/nd2sk ◽

2021 ◽

Author(s):

Joseph Angel De Soto ◽

Gabriel Selassie ◽

Gilberta Yazzie

Keyword(s):

Health Care ◽

Clinical Trials ◽

Native American ◽

African Americans ◽

Native Americans ◽

Ethnic Minorities ◽

Health Care Disparities ◽

The United States ◽

Cancer Clinical Trials ◽

Unnecessary Death

Introduction: A major source of health care disparities derives from the underrepresentation of ethnic minorities in clinical trials. The inclusion of ethnic minorities is necessary to generalize the results in terms of efficacy and toxicology of medications in cancer treatment. Methodology: In this retrospective study, 80 cancer clinical trials with an aggregate of 278,470 participants performed within the last ten years were selected at random. The number of ethnic minorities participating and inclusion of them in the results were evaluated. Results: Only, 42.5% of cancer clinical trials reported the ethnic background of participants in their trials while even less 5% reported the efficacy or toxicology of the therapeutic intervention for ethnic minorities. Whites, Hispanics, African Americans, and Native Americans make up 60.1%, 18.5%, 13.4% and 1.5% of the population they made up 85.3%, 2.54%, 7.6% and 0.12% of the participants that reported ethnicity, respectively. Out of 278,470 participants in cancer clinicals trials only 133 (0.048%) could be identified as Native American . Conclusion: Native Americans were nearly completely excluded from cancer clinical trials. African Americans and Hispanics were greatly underrepresented. Cancer Clinical trials may not be generalizable and have been inherently racist in the United States. This has led to the unnecessary death and suffering of Native Americans from cancer.

Download Full-text